All In Biotech

Drug Trial Radar · NCT02632708

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

153

Actual

Start

Dec 31, 2015

Primary completion

Dec 13, 2018

Study completion Jul 24, 2026

Sponsor

Lead sponsor
Institut de Recherches Internationales ServierAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Celgene Corporation
First posted
Dec 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML induction and consolidation therapy. The study plans to evaluate up to 2 dose levels of AG-120 in participants with an isocitrate dehydrogenase protein 1 (IDH1) mutation and up to 2 dose levels of AG-221 in participants with an isocitrate dehydrogenase protein 2 (IDH2) mutation. AG-120 or AG-221 will be administered with 2 types of AML induction therapies (cytarabine with either daunorubicin or idarubicin) and 2 types of AML consolidation therapies (mitoxantrone with etoposide \[ME\] or cytarabine). After consolidation therapy, participants may continue on to maintenance therapy and receive daily treatment with single-agent AG-120 or AG-221 until relapse, development of an unacceptable toxicity, or hematopoietic stem cell transplant (HSCT). The study will end when all participants have discontinued study treatment.

Conditions

  • Newly Diagnosed Acute Myeloid Leukemia (AML)
  • Untreated AML
  • AML Arising From Myelodysplastic Syndrome (MDS)
  • AML Arising From Antecedent Hematologic Disorder (AHD)
  • AML Arising After Exposure to Genotoxic Injury

Interventions

  • AG-120Drug

  • AG-221Drug

  • cytarabineDrug

  • daunorubicinDrug

  • idarubicinDrug

  • mitoxantroneDrug

  • etoposideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Adverse Events (AEs)Time frame: Up to 26 weeks

Locations

17 sites in 3 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • UCLA Medical Center

    Los Angeles, California

  • University of Colorado

    Aurora, Colorado

  • University of Chicago

    Chicago, Illinois

  • Johns Hopkins University

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Ohio State University

    Columbus, Ohio

  • Medical University of South Carolina - PPDS

    Charleston, South Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Universitatsklinikum Ulm

    Ulm, Germany

  • VU Medisch Centrum

    Amsterdam, Netherlands

  • Erasmus MC

    Rotterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.